Amarin Corporation PLC (NASDAQ:AMRN) Earning Somewhat Positive News Coverage, Accern Reports
Media stories about Amarin Corporation PLC (NASDAQ:AMRN) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Amarin Corporation PLC earned a daily sentiment score of 0.09 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.3818392326806 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news articles that may have impacted Accern Sentiment’s scoring:
- Amarin Corporation PLC (AMRN) Issues Earnings Results, Beats Expectations By $0.01 EPS – ExpressNewsline (expressnewsline.com)
- Healthcare Stock on Buy Line: Amarin Corporation plc (AMRN) – Street Observer (press release) (streetobserver.com)
- Amarin Corporation plc (AMRN) stands -9.72% away from 50 SMA: Technical Watch: Amarin Corporation plc (AMRN) – Voice Of Analysts (analystsbuzz.com)
- Zacks: Brokerages Expect Amarin Corporation PLC (NASDAQ:AMRN) to Post -$0.05 EPS (americanbankingnews.com)
- Investor Update: Company Share Focus for Amarin Corporation PLC (NASDAQ:AMRN) – Jonesboro Recorder (jonesbororecorder.com)
Shares of Amarin Corporation PLC (NASDAQ:AMRN) opened at 3.26 on Friday. The company has a 50-day moving average of $3.87 and a 200 day moving average of $3.32. The stock’s market capitalization is $882.78 million. Amarin Corporation PLC has a 12-month low of $2.56 and a 12-month high of $4.47.
Amarin Corporation PLC (NASDAQ:AMRN) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.01. The company had revenue of $44.95 million for the quarter, compared to analysts’ expectations of $40.35 million. The firm’s revenue was up 37.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.07) earnings per share. Analysts predict that Amarin Corporation PLC will post ($0.22) earnings per share for the current year.
AMRN has been the subject of several research reports. Zacks Investment Research raised shares of Amarin Corporation PLC from a “sell” rating to a “hold” rating in a research report on Monday, July 3rd. BidaskClub lowered shares of Amarin Corporation PLC from a “buy” rating to a “hold” rating in a report on Saturday, August 5th. Cantor Fitzgerald reissued an “overweight” rating and issued a $10.00 target price on shares of Amarin Corporation PLC in a report on Monday, June 26th. Jefferies Group LLC started coverage on shares of Amarin Corporation PLC in a report on Thursday, June 29th. They issued a “reduce” rating and a $3.50 target price for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Amarin Corporation PLC in a report on Thursday, June 1st. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $7.35.
In related news, General Counsel Joseph T. Kennedy sold 307,911 shares of Amarin Corporation PLC stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $4.00, for a total transaction of $1,231,644.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 3.72% of the stock is currently owned by company insiders.
Amarin Corporation PLC Company Profile
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Receive News & Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.